- Adjusted EPS for Alnylam was 56 cents, beating both last year’s loss per share of $1.62 and the estimated loss per share of 73 cents.
- Loss per share was reduced to 13 cents from last year’s $2.21, and it was better than the estimated loss per share of $1.06.
- Revenue surged to $659.8 million from $318.8 million last year, outperforming the estimate of $447.6 million.
- Net product revenues increased by 34% year over year to $410.1 million, surpassing the estimate of $366.4 million.
- Onpattro net product revenues fell by 16% year over year to $77.2 million, but still exceeded the estimate of $58.3 million.
- Givlaari net product revenues grew by 7.3% year over year to $62.1 million, slightly missing the estimate of $64 million.
- Oxlumo net product revenues surged by 68% year over year to $40.6 million, beating the estimate of $37 million.
- Collaboration revenue skyrocketed to $227.3 million from $5.84 million last year, substantially exceeding the estimate of $63.4 million.
- Operating expenses increased by 11% year over year to $611.2 million, higher than the estimate of $552.1 million.
- Cash and cash equivalents rose by 47% year over year to reach $968.5 million, surpassing the estimate of $649 million.
- AMVUTTRA net product revenue jumped by 74% year over year to $230.1 million, exceeding the estimate of $205.8 million.
- Adjusted R&D expenses were close to estimates, standing at $246.0 million versus the estimated $245.1 million.
- Analyst recommendations include 20 buys, 10 holds, and 0 sells.
Alnylam Pharmaceuticals on Smartkarma
A look at Alnylam Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company that is focusing on developing innovative technology to silence disease-causing genes effectively. According to the Smartkarma Smart Scores, the company receives a high rating in Growth, Resilience, and Momentum, indicating a positive long-term outlook. With a strong emphasis on growth potential, resilience in adverse market conditions, and positive momentum in the market, Alnylam Pharmaceuticals is positioned well for future success.
Although the company does not score well in terms of traditional value or dividend payments, its focus on growth, resilience, and momentum suggests that investors looking for long-term growth potential may find Alnylam Pharmaceuticals an attractive investment opportunity. The company’s innovative approach to addressing disease-causing genes and its strong performance in key areas point towards a promising future ahead.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
